Literature DB >> 35571985

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma.

Leon D Kaulen1,2, Christoph Gumbinger1, Felix Hinz3,4, Tobias Kessler1,2, Frank Winkler1,2, Martin Bendszus5, Felix Sahm3,4, Wolfgang Wick1,2.   

Abstract

Entities:  

Year:  2022        PMID: 35571985      PMCID: PMC9092640          DOI: 10.1093/noajnl/vdac051

Source DB:  PubMed          Journal:  Neurooncol Adv        ISSN: 2632-2498


× No keyword cloud information.
  12 in total

1.  Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Authors:  Stephen M Ansell; Monique C Minnema; Peter Johnson; John M Timmerman; Philippe Armand; Margaret A Shipp; Scott J Rodig; Azra H Ligon; Margaretha G M Roemer; Nishitha Reddy; Jonathon B Cohen; Sarit Assouline; Michelle Poon; Manish Sharma; Kazunobu Kato; Selda Samakoglu; Anne Sumbul; Andrew Grigg
Journal:  J Clin Oncol       Date:  2019-01-08       Impact factor: 44.544

2.  Exome sequencing identifies SLIT2 variants in primary CNS lymphoma.

Authors:  Leon D Kaulen; E Zeynep Erson-Omay; Octavian Henegariu; Philipp Karschnia; Anita Huttner; Murat Günel; Joachim M Baehring
Journal:  Br J Haematol       Date:  2021-01-22       Impact factor: 6.998

Review 3.  The Brain's Glymphatic System: Current Controversies.

Authors:  Humberto Mestre; Yuki Mori; Maiken Nedergaard
Journal:  Trends Neurosci       Date:  2020-05-15       Impact factor: 13.837

4.  A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.

Authors:  Jeffrey J Iliff; Minghuan Wang; Yonghong Liao; Benjamin A Plogg; Weiguo Peng; Georg A Gundersen; Helene Benveniste; G Edward Vates; Rashid Deane; Steven A Goldman; Erlend A Nagelhus; Maiken Nedergaard
Journal:  Sci Transl Med       Date:  2012-08-15       Impact factor: 17.956

5.  PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Authors:  Lakshmi Nayak; Fabio M Iwamoto; Ann LaCasce; Srinivasan Mukundan; Margaretha G M Roemer; Bjoern Chapuy; Philippe Armand; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2017-03-29       Impact factor: 22.113

6.  Widespread brain distribution and activity following i.c.v. infusion of anti-β-secretase (BACE1) in nonhuman primates.

Authors:  Daniela Bumbaca Yadav; Janice A Maloney; Kristin R Wildsmith; Reina N Fuji; William J Meilandt; Hilda Solanoy; Yanmei Lu; Kun Peng; Blair Wilson; Pamela Chan; Kapil Gadkar; Andrew Kosky; Marisa Goo; Ann Daugherty; Jessica A Couch; Thomas Keene; Karen Hayes; Lisa Jungbauer Nikolas; Deanna Lane; Robert Switzer; Eric Adams; Ryan J Watts; Kimberly Scearce-Levie; Saileta Prabhu; Lisa Shafer; Deepak R Thakker; Keith Hildebrand; Jasvinder K Atwal
Journal:  Br J Pharmacol       Date:  2017-10-06       Impact factor: 8.739

7.  Targetable genetic features of primary testicular and primary central nervous system lymphomas.

Authors:  Bjoern Chapuy; Margaretha G M Roemer; Chip Stewart; Yuxiang Tan; Ryan P Abo; Liye Zhang; Andrew J Dunford; David M Meredith; Aaron R Thorner; Ekaterina S Jordanova; Gang Liu; Friedrich Feuerhake; Matthew D Ducar; Gerald Illerhaus; Daniel Gusenleitner; Erica A Linden; Heather H Sun; Heather Homer; Miyuki Aono; Geraldine S Pinkus; Azra H Ligon; Keith L Ligon; Judith A Ferry; Gordon J Freeman; Paul van Hummelen; Todd R Golub; Gad Getz; Scott J Rodig; Daphne de Jong; Stefano Monti; Margaret A Shipp
Journal:  Blood       Date:  2015-12-23       Impact factor: 22.113

8.  Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.

Authors:  Dick Pluim; Willeke Ros; Mark T J van Bussel; Dieta Brandsma; Jos H Beijnen; Jan H M Schellens
Journal:  J Pharm Biomed Anal       Date:  2018-10-17       Impact factor: 3.935

9.  Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

Authors:  James L Rubenstein; Jing Li; Lingjing Chen; Ranjana Advani; Jan Drappatz; Elizabeth Gerstner; Tracy Batchelor; Hendrikus Krouwer; James Hwang; Glenna Auerback; Cigall Kadoch; Clifford Lowell; Pamela Munster; Soonmee Cha; Marc A Shuman; Lloyd E Damon
Journal:  Blood       Date:  2012-11-29       Impact factor: 22.113

10.  High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Authors:  K Fritsch; B Kasenda; E Schorb; P Hau; J Bloehdorn; R Möhle; S Löw; M Binder; J Atta; U Keller; H-H Wolf; S W Krause; G Heß; R Naumann; S Sasse; C Hirt; M Lamprecht; U Martens; A Morgner; J Panse; N Frickhofen; A Röth; C Hader; M Deckert; H Fricker; G Ihorst; J Finke; G Illerhaus
Journal:  Leukemia       Date:  2016-11-15       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.